Work

Diagnostic and prognostic value of microRNA-628 for cancers

Year: 2018

Type: article

Study designs: Systematic Review, Meta-Analysis

Abstract: Background: Many studies manifested miRNA-628 (miR-628) was deregulated in various cancers, indicating that miR-628 might serve as a novel biomarker of cancer diagnosis and prognosis, but it's role was still uncertain.This study aimed to evaluate the value of miR-628 in various cancers for diagnosis and prognosis, as well as its predictive power in combination biomarkers. Materials and Methods:A literature search was performed using Medline (via PubMed), Embase, Web of Science databases, and Ovid platform up to November 2017.Meta-analysis was performed to provide summative outcomes.Quality assessment of each included study was performed.Results: Twelve articles with 20 studies were included in our meta-analysis, including 8 articles with 15 studies for diagnostic meta-analysis and 4 articles with 5 studies for prognostic meta-analysis.For the diagnostic meta-analysis of miR-628 alone, the overall pooled results for sensitivity, specificity, positive likelihood ratio (PLR), negative likelihood ratio (NLR), diagnostic odds ratio (DOR), and the area under the summary receiver operating characteristic (SROC) curve (AUC) were 0.81 (95% CI: 0.62-0.91),0.72 (95% CI: 0.48-0.88),2.90 (95% CI: 1.50-5.40),0.27 (95% CI: 0.14-0.50),11.0 (95% CI: 4.00-25.00),and 0.84 (95% CI: 0.80-0.87),respectively.For the diagnostic meta-analysis of miR-628-related combination biomarkers, the above six parameters were 0.89 (95% CI: 0.84-0.92),0.93 (95% CI: 0.82-0.97),12.30 (95% CI: 4.70-32.50),0.12 (95% CI: 0.08-0.19),and 100.00 (95% CI: 28.00-354.00),0.93 (95% CI: 0.90-0.95),respectively.For the prognostic meta-analysis, patients with lower miR-628 had significant shorter overall survival than high expression of miR-628 (HR = 1.553, 95% CI: 1.041-2.318,z = 2.16, P = 0.031).Conclusions: This study confirms that miR-628 may be a promising biomarker for cancer diagnosis and prognosis.Expertly, microRNAs combination biomarkers could be a new alternative for clinical application.

Source: Journal of Cancer

DOI: 10.7150/jca.24193